A huge part of the saving was made up by AbbVie’s Humira losing its patent.
News
AbbVie discontinues Rova-T programme
An Independent Data Monitoring Committee recommended terminating the trial, following a failure to demonstrate survival benefit.
EU nod for Giapreza
In July the EMA’s CHMP supported granting a marketing authorisation for the drug.
Immunicum’s ilixadencel successful in kidney cancer
The drug achieved complete tumour responses in five out of 45 metastatic kidney cancer patients, compared to one in 25.
White matter affects response to brain stimulation therapy
The team ultimately found that “people with stronger white matter connections in their brain had better improvement with stimulation.”
EMA recommends new methotrexate measures
The Pharmacovigilance Risk Assessment Committee initially recommended new measures in July.
Amgen to acquire Celgene’s Otezla
The transaction is expected to close by the end of 2019.
FDA green light for Fasenra
Currently there are no FDA-approved treatments for eosinophilic oesophagitis.
AZ bags positive results in investigational Lupus drug trial
The drug achieved a statistically-significant and clinically-meaningful reduction in disease activity.
EU approval for Tecentriq combo
The approval of the monoclonal antibody was based on results from the Phase III IMpassion130 study.
Entry closing in just over 2 weeks for the 2019 Communications Team of the Year competition!
Entry for the 2019 PharmaTimes Communications Team of the Year competition will be closing on the 16th of September.
Ionis to license hep B programme to GSK
GSK is now responsible for all development, regulatory and commercialisation activities and costs.
AZ’ triple combo hits endpoint in COPD trial
Breztri Aerosphere – formerly known as PT010 – showed a 52% reduction in exacerbations.
NICE updates hypertension guideline
The clinical management of hypertension accounts for 12% of visits to primary care and up to £2.1 billion of healthcare expenditure.
Empliciti combo bags EU approval for multiple myeloma
The approval is based on data from the ELOQUENT-3 trial.
